Heart and Blood Diseases

All Conditions

Hypertension

Vascular Diseases

All Drugs and Chemicals

Anti-Arrhythmia Agents

Antihypertensive Agents

Cardiotonic Agents

Vasoconstrictor Agents

Anti-Infective Agents

Hormones

Losartan

Lisinopril

Ramipril

Angiotensin-Converting Enzyme Inhibitors

Benazepril

Angiotensin II

Giapreza

Angiotensinogen

Angiotensin II Type 1 Receptor Blockers

Angiotensin Receptor Antagonists

Enzyme Inhibitors

HIV Protease Inhibitors

Protease Inhibitors

Protective Agents

Patients receive oral benazepril hydrochloride once daily on days 1-7.

Patients receive oral lisinopril once daily on days 1-7.

Patients receive oral ramipril twice daily on days 1-7.

Patients receive oral losartan potassium once daily on days 1-7.

lisinopril

losartan potassium

laboratory biomarker analysis

benazepril hydrochloride

ramipril

William Petty

RATIONALE: Benazepril hydrochloride, lisinopril, ramipril, and losartan potassium may help lower blood pressure.

PURPOSE: This phase II trial is studying how well benazepril hydrochloride, lisinopril, ramipril, or losartan potassium works in treating hypertension in patients with solid tumors.

PRIMARY OBJECTIVES:

I. To determine which drug has the greatest effect on Ang-(1-7) levels in cancer patients with hypertension.

SECONDARY OBJECTIVES:

I. To determine the effect of these drugs on levels of Ang II, VEGF, PlGF, and ACE in the same patients.

OUTLINE: Patients are randomized to 1 of 4 treatment arms.

* ARM I: Patients receive oral benazepril hydrochloride once daily on days 1-7.
* ARM II: Patients receive oral lisinopril once daily on days 1-7.
* ARM III: Patients receive oral ramipril twice daily on days 1-7.
* ARM IV: Patients receive oral losartan potassium once daily on days 1-7. In all arms, treatment continues in the absence of unacceptable toxicity.

Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors

A Phase II Study of the Effect of ACE Inhibitors on Pro-Angiogenic Hormones in Cancer Patients With Hypertension

Wake Forest University Health Sciences

Patients receive oral benazepril hydrochloride once daily on days 1-7.

laboratory biomarker analysis: Correlative studies

benazepril hydrochloride: Given orally

Arm I

Patients receive oral lisinopril once daily on days 1-7.

lisinopril: Given orally

laboratory biomarker analysis: Correlative studies

Arm II

Patients receive oral ramipril twice daily on days 1-7.

laboratory biomarker analysis: Correlative studies

ramipril: Given orally

Arm III

Patients receive oral losartan potassium once daily on days 1-7.

losartan potassium: Given orally

laboratory biomarker analysis: Correlative studies

Arm IV

Total

Age, Categorical

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

United States

Region of Enrollment

William J. Petty, MD

Changes in Ang1-7 Levels Among Patients After ACE-I/ARB Treatment Measured in Picogram/Milliliter

Data were not analyzed due to insufficient accrual to the study and lack of statistical power.

Change in Ang II, VEGF, PlGF, and ACE Levels

Overall Study

Spots Global Cancer Trial Database for benazepril hydrochloride